根治性前列腺切除术后持续性前列腺特异性抗原对原发N0前列腺癌患者挽救性放疗疗效的影响
该研究评估555例N0前列腺癌患者根治性前列腺切除术后行挽救性放疗的无进展生存,中位随访6.1年。PSA持续存在和放疗前PSA≥0.5 ng/mL均显著降低无进展生存率,但多因素分析中仅放疗前PSA水平而非术后PSA持续存在为显著参数。结论认为术后PSA持续存在者早期挽救性放疗(PSA<0.5 ng/mL)似乎效果较差,可能需要强化治疗,但需更大样本量证实。
要点
- 根治性前列腺切除术后PSA持续存在和放疗前PSA≥0.5 ng/mL显著降低挽救性放疗后的无进展生存率。
- 多因素分析中,放疗前PSA水平而非术后PSA持续存在是显著参数。
- 术后PSA持续存在者早期挽救性放疗(PSA<0.5 ng/mL)似乎效果较差,可能受益于强化治疗。
核心结论
- 在N0前列腺癌术后PSA持续存在的患者中,PSA<0.5 ng/mL时早期挽救性放疗似乎比术后PSA不可测的复发患者效果更差。
- 这些患者可能受益于强化治疗,但需要更大样本量来证实该结论。
- 对于PSA≥0.5 ng/mL且伴有与术后PSA持续存在相关的高危特征的患者,单纯挽救性放疗不太可能提供长期无进一步进展。
研究设计与样本
- 评估555例前列腺癌患者挽救性放疗后的PSA进展无生存期(PFS)。
- 将整个队列与112对风险调整匹配患者亚组进行比较,匹配因素包括术前PSA水平(±10 ng/mL)、Gleason评分(≤6 vs 7 vs ≥8)和放疗前PSA水平(±0.5 ng/mL)。
主要发现
- 中位随访时间为6.1年。
- 根治性前列腺切除术后,422例患者PSA不可测,133例患者PSA持续存在。
- PSA持续存在和放疗前PSA水平≥0.5 ng/mL显著降低Kaplan-Meier法估算的PFS率。
- 在整个队列的多因素分析和风险调整后,放疗前PSA水平而非术后PSA持续存在是显著参数。
- 在匹配队列中接受PSA<0.5 ng/mL早期挽救性放疗的亚组中,观察到术后PSA持续存在与更差结局的趋势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大样本量来证实术后PSA持续存在者可能受益于强化治疗的结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test whether salvage radiotherapy (SRT) in patients with lymph node negative (N0) prostate cancer is equally effective with persistent prostate-specific antigen (PSA) and PSA rising from the undetectable range (<0.1 ng/mL) after radical prostatectomy (RP). PATIENTS AND METHODS: We assessed post-SRT PSA progression-free survival (PFS) in 555 patients with prostate cancer. The entire cohort was compared with a risk-adjusted subgroup of 112 patient pairs with matching pre-RP PSA level (±10 ng/mL), Gleason score (≤6 vs 7 vs ≥8), and pre-SRT PSA level (±0.5 ng/mL). RESULTS: The median follow-up was 6.1 years. After RP, PSA was undetectable in 422 and persistent in 133 patients. PSA persistence and a pre-SRT PSA level of ≥0.5 ng/mL reduced Kaplan-Meier rates of PFS significantly. In multivariate analysis of the entire cohort and after risk adjustment, the pre-SRT PSA level but not post-RP PSA persistence was a significant parameter. In the matched cohort's subgroup with early SRT at a PSA level of <0.5 ng/mL, a trend towards a worse outcome with post-RP PSA persistence was observed. Delayed SRT with a PSA level ≥0.5 ng/mL led to a PFS of <30%, irrespective of the post-RP PSA level. CONCLUSION: In patients with N0 prostate cancer with post-RP PSA persistence, early SRT at a PSA level <0.5 ng/mL seems to be less effective than in recurrent patients with post-RP undetectable PSA. They might benefit from intensified therapy, but larger case numbers are required to substantiate this conclusion. In patients with a PSA level ≥0.5 ng/mL and higher-risk features associated with post-RP PSA persistence, SRT alone is unlikely to provide long-term freedom from further progression.
引用
- Bartkowiak D, Siegmann A, Böhmer D, et al. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer. BJU Int. 2019. PMID: 31220400. doi:10.1111/bju.14851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。